Entity
  • Herantis Pharma Plc.

    Created in 2008
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    4,272
  • Activities

  • Technologies

  • Entity types

  • Location

    Bertel Jungin aukio 1, 02600 Espoo, Finland

    Espoo

    Finland

  • Employees

    Scale: 11-50

    Estimated: 21

  • Engaged corporates

    1
    0 1
  • Added in Motherbase

    3 months, 2 weeks ago
Description
  • Value proposition

    Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s.

    Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

    Parkinson's disease, Neurodegenerative diseases, Biologics, biotech, and drug development

  • Herantis Pharma - Innovative therapies for better lives

    Herantis Pharma is a publicly listed drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs.

  • https://herantis.com/
Corporate interactions BETA
Corporate TypeTweets Articles
PharmaTimes Media Ltd
PharmaTimes Media Ltd
Pharmaceutical, Pharmaceutical Manufacturing
PharmaTimes Media Ltd
Pharmaceutical, Pharmaceutical Manufacturing
Other

7 Jul 2024


Similar entities
Loading...
Loading...
Social network dynamics